EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder
NinaMED Pty Ltd has announced its establishment and secured US$13.75 million in financing to develop and commercialize the NiNA System®, a non-invasive therapy for overactive bladder (OAB), under a license from EBT Medical. The funds will accelerate the NiNA System® development and support a path towards an Investigational Device Exemption Application, marking a significant milestone in addressing the needs of OAB patients, affecting an estimated 550 million worldwide.
US$13.75M financing completed to accelerate clinical pathway and global commercialisation Establishment of NinaMED Pty Ltd, a new Australian medtech company NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB therapy…